Ultrasound Guided Erector Spinae Block Versus Ultrasound Guided Thoracic Paravertebral Block for Pain Relief in Patients With Acute Thoracic Herpes Zoster
Overview
- Phase
- Phase 4
- Intervention
- Control Rx
- Conditions
- Acute Thoracic Herpes Zoster
- Sponsor
- Tanta University
- Enrollment
- 90
- Locations
- 1
- Primary Endpoint
- The incidence of post herpetic neuralgia (PHN)
- Last Updated
- 5 years ago
Overview
Brief Summary
The aim of this research is to study and compare the efficacy and safety of single injection erector spinae plane block and thoracic paravertebral block in prevention of post herpetic neuralgia in patients with acute thoracic herpes zoster.
Investigators
Esraa Hassan Abdelwahab
Assistant lecturer of Anesthesiology, Surgical Intensive Care and Pain Medicine
Tanta University
Eligibility Criteria
Inclusion Criteria
- •Over 50 years of age
- •Chest wall herpetic eruption of less than one week
- •Moderate or severe pain
Exclusion Criteria
- •Patient refusal
- •Eruption more than one week duration
- •Patients who will not receive appropriate anti-viral therapy
- •Patients with mild pain
- •Infection at the site of injection
- •Patients with a history of renal, hepatic diseases, coagulopathy, steroid therapy, malignancies.
- •Patient taking chemotherapy and/or radiotherapy.
Arms & Interventions
Control Group
Patients of this group will receive standard treatment for herpes zoster which include acyclovir 800 mg, 5 times daily administered orally within the first 72 hours and analgesics as needed.
Intervention: Control Rx
Erector Spinae Block (ESB) group
Patients of this group will receive 25 mg bupivacaine 0.5%, plus 8 mg dexamethasone in a total volume of 10 ml (The final Patients of this group will receive 25 mg bupivacaine 0.5%, plus 8 mg dexamethasone in a total volume of 10 ml(The final concentration of bupivacaine will be 0.25%) to be injected beneath the erector spinae muscle sheath) at the desired level under ultrasonography. The concentration of bupivacaine will be 0.25%) to be injected beneath the erector spinae muscle sheath) at the desired level under ultrasonography.
Intervention: Erector Spinae Block
Thoracic Paravertebral Block group
Patients will receive 25 mg bupivacaine 0.5%, plus 8mg dexamethasone in a total volume of 10 ml(The final concentration of bupivacaine will be 0.25%) to be injected in the Paravertebral space at the desired level under ultrasonography
Intervention: Thoracic Paravertebral Block
Outcomes
Primary Outcomes
The incidence of post herpetic neuralgia (PHN)
Time Frame: 3 months
Persistent herpetic pain after 3 months will reported as post herpetic neuralgia (PHN)
Secondary Outcomes
- Visual Analog Scale(6 months)
- Total consumption of rescue analgesia(6 months)
- The times of complete resolution of pain(3 months)
- Adverse effects and complications(1 day)